 | • レポートコード：MRC309Z7890 • 出版社/出版日：GlobalInfoResearch / 2023年9月 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| GlobalInfoResearchの最新の調査によると、世界の神経芽腫における免疫療法薬の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。 このレポートは、世界の神経芽腫における免疫療法薬市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。 市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。 本レポートの主な目的は次のとおりです。 - 世界および主要国の市場機会の規模を決定するため - 神経芽腫における免疫療法薬の成長可能性を評価するため - 各製品および最終用途市場の将来の成長を予測するため - 市場に影響を与える競争要因を評価するため 神経芽腫における免疫療法薬市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメント ・ジヌツキシマブ、ナキシタマブ、その他 用途別セグメント ・病院、診療所、その他 主要な市場プレーヤー ・United Therapeutics、Y-mAbs Therapeutics、EUSA Pharma、ANI Pharmaceuticals、Baxter Healthcare、Ingenus Pharmaceuticals、Pfizer、Hikma Pharmaceuticals、Teva Pharmaceuticals 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、神経芽腫における免疫療法薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な神経芽腫における免疫療法薬メーカーの企業概要、2019年～2022年までの神経芽腫における免疫療法薬の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な神経芽腫における免疫療法薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2018年～2029年までの地域別神経芽腫における免疫療法薬の販売量、売上、成長性を示しています。 ・第5、6章では、2018年～2029年までの神経芽腫における免疫療法薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での神経芽腫における免疫療法薬市場予測を収録しています。 ・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。 ・第13章では、主要な原材料、主要なサプライヤー、および神経芽腫における免疫療法薬の産業チェーンを掲載しています。 ・第14、15章では、神経芽腫における免疫療法薬の販売チャネル、販売業者、顧客、調査結果について説明します。 ***** 目次(一部) ***** ・市場概要 - 神経芽腫における免疫療法薬の概要 - 種類別分析（2018年vs2022年vs2029年）：ジヌツキシマブ、ナキシタマブ、その他 - 用途別分析（2018年vs2022年vs2029年）：病院、診療所、その他 - 世界の神経芽腫における免疫療法薬市場規模・予測 - 世界の神経芽腫における免疫療法薬生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - United Therapeutics、Y-mAbs Therapeutics、EUSA Pharma、ANI Pharmaceuticals、Baxter Healthcare、Ingenus Pharmaceuticals、Pfizer、Hikma Pharmaceuticals、Teva Pharmaceuticals ・メーカー別市場シェア・市場集中度 ・地域別市場分析2018年-2029年 ・種類別分析2018年-2029年：ジヌツキシマブ、ナキシタマブ、その他 ・用途別分析2018年-2029年：病院、診療所、その他 ・神経芽腫における免疫療法薬の北米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・神経芽腫における免疫療法薬のヨーロッパ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・神経芽腫における免疫療法薬のアジア市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・神経芽腫における免疫療法薬の南米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・神経芽腫における免疫療法薬の中東・アフリカ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析） ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
According to our (Global Info Research) latest study, the global Immunotherapy Drugs for Neuroblastoma market size was valued at USD 46 million in 2022 and is forecast to a readjusted size of USD 63 million by 2029 with a CAGR of 4.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient’s age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
This report is a detailed and comprehensive analysis for global Immunotherapy Drugs for Neuroblastoma market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Immunotherapy Drugs for Neuroblastoma market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Immunotherapy Drugs for Neuroblastoma market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Immunotherapy Drugs for Neuroblastoma market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Immunotherapy Drugs for Neuroblastoma market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Immunotherapy Drugs for Neuroblastoma
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Immunotherapy Drugs for Neuroblastoma market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals and Baxter Healthcare, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Immunotherapy Drugs for Neuroblastoma market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Dinutuximab
Naxitamab
Other
Market segment by Application
Hospital
Clinic
Other
Major players covered
United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Immunotherapy Drugs for Neuroblastoma product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Immunotherapy Drugs for Neuroblastoma, with price, sales, revenue and global market share of Immunotherapy Drugs for Neuroblastoma from 2018 to 2023.
Chapter 3, the Immunotherapy Drugs for Neuroblastoma competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Immunotherapy Drugs for Neuroblastoma breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Immunotherapy Drugs for Neuroblastoma market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Immunotherapy Drugs for Neuroblastoma.
Chapter 14 and 15, to describe Immunotherapy Drugs for Neuroblastoma sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Immunotherapy Drugs for Neuroblastoma
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Dinutuximab
1.3.3 Naxitamab
1.3.4 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Other
1.5 Global Immunotherapy Drugs for Neuroblastoma Market Size & Forecast
1.5.1 Global Immunotherapy Drugs for Neuroblastoma Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity (2018-2029)
1.5.3 Global Immunotherapy Drugs for Neuroblastoma Average Price (2018-2029)
2 Manufacturers Profiles
2.1 United Therapeutics
2.1.1 United Therapeutics Details
2.1.2 United Therapeutics Major Business
2.1.3 United Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
2.1.4 United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 United Therapeutics Recent Developments/Updates
2.2 Y-mAbs Therapeutics
2.2.1 Y-mAbs Therapeutics Details
2.2.2 Y-mAbs Therapeutics Major Business
2.2.3 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
2.2.4 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Y-mAbs Therapeutics Recent Developments/Updates
2.3 EUSA Pharma
2.3.1 EUSA Pharma Details
2.3.2 EUSA Pharma Major Business
2.3.3 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product and Services
2.3.4 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 EUSA Pharma Recent Developments/Updates
2.4 ANI Pharmaceuticals
2.4.1 ANI Pharmaceuticals Details
2.4.2 ANI Pharmaceuticals Major Business
2.4.3 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.4.4 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 ANI Pharmaceuticals Recent Developments/Updates
2.5 Baxter Healthcare
2.5.1 Baxter Healthcare Details
2.5.2 Baxter Healthcare Major Business
2.5.3 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product and Services
2.5.4 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Baxter Healthcare Recent Developments/Updates
2.6 Ingenus Pharmaceuticals
2.6.1 Ingenus Pharmaceuticals Details
2.6.2 Ingenus Pharmaceuticals Major Business
2.6.3 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.6.4 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Immunotherapy Drugs for Neuroblastoma Product and Services
2.7.4 Pfizer Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Pfizer Recent Developments/Updates
2.8 Hikma Pharmaceuticals
2.8.1 Hikma Pharmaceuticals Details
2.8.2 Hikma Pharmaceuticals Major Business
2.8.3 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.8.4 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Hikma Pharmaceuticals Recent Developments/Updates
2.9 Teva Pharmaceuticals
2.9.1 Teva Pharmaceuticals Details
2.9.2 Teva Pharmaceuticals Major Business
2.9.3 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.9.4 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Teva Pharmaceuticals Recent Developments/Updates
3 Competitive Environment: Immunotherapy Drugs for Neuroblastoma by Manufacturer
3.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Manufacturer (2018-2023)
3.2 Global Immunotherapy Drugs for Neuroblastoma Revenue by Manufacturer (2018-2023)
3.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Immunotherapy Drugs for Neuroblastoma by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Immunotherapy Drugs for Neuroblastoma Manufacturer Market Share in 2022
3.4.2 Top 6 Immunotherapy Drugs for Neuroblastoma Manufacturer Market Share in 2022
3.5 Immunotherapy Drugs for Neuroblastoma Market: Overall Company Footprint Analysis
3.5.1 Immunotherapy Drugs for Neuroblastoma Market: Region Footprint
3.5.2 Immunotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
3.5.3 Immunotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Immunotherapy Drugs for Neuroblastoma Market Size by Region
4.1.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2029)
4.1.2 Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2029)
4.1.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Region (2018-2029)
4.2 North America Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.3 Europe Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.4 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.5 South America Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.6 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
5.2 Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type (2018-2029)
5.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
6.2 Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application (2018-2029)
6.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029)
7 North America
7.1 North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
7.2 North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
7.3 North America Immunotherapy Drugs for Neuroblastoma Market Size by Country
7.3.1 North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
7.3.2 North America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
8.2 Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
8.3 Europe Immunotherapy Drugs for Neuroblastoma Market Size by Country
8.3.1 Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
8.3.2 Europe Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Market Size by Region
9.3.1 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
10.2 South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
10.3 South America Immunotherapy Drugs for Neuroblastoma Market Size by Country
10.3.1 South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
10.3.2 South America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Market Size by Country
11.3.1 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Immunotherapy Drugs for Neuroblastoma Market Drivers
12.2 Immunotherapy Drugs for Neuroblastoma Market Restraints
12.3 Immunotherapy Drugs for Neuroblastoma Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Immunotherapy Drugs for Neuroblastoma and Key Manufacturers
13.2 Manufacturing Costs Percentage of Immunotherapy Drugs for Neuroblastoma
13.3 Immunotherapy Drugs for Neuroblastoma Production Process
13.4 Immunotherapy Drugs for Neuroblastoma Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Immunotherapy Drugs for Neuroblastoma Typical Distributors
14.3 Immunotherapy Drugs for Neuroblastoma Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
